Matches in Wikidata for { <http://www.wikidata.org/entity/Q66065970> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q66065970 description "clinical trial" @default.
- Q66065970 description "ensayu clínicu" @default.
- Q66065970 description "klinisch onderzoek" @default.
- Q66065970 description "клінічне випробування" @default.
- Q66065970 name "A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment" @default.
- Q66065970 name "A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment" @default.
- Q66065970 type Item @default.
- Q66065970 label "A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment" @default.
- Q66065970 label "A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment" @default.
- Q66065970 prefLabel "A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment" @default.
- Q66065970 prefLabel "A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment" @default.
- Q66065970 P1050 Q66065970-55F274D3-4D4E-4964-8BF1-87F64BEEBBD5 @default.
- Q66065970 P1132 Q66065970-D3A4C5A1-C54D-4656-B04C-145FA0419A60 @default.
- Q66065970 P1476 Q66065970-C65E7799-A769-44AF-9512-23B70FEF23A2 @default.
- Q66065970 P17 Q66065970-70D4ED36-5DE7-4F86-8C45-6A71F8DFE011 @default.
- Q66065970 P2899 Q66065970-66B6F0FE-1EFB-4C0E-B7E8-A0F8F5467138 @default.
- Q66065970 P3098 Q66065970-0ED43B0C-0847-4B73-B7CD-E7FD6725BBBA @default.
- Q66065970 P31 Q66065970-04741389-E6D9-4773-A965-315F7C22A752 @default.
- Q66065970 P580 Q66065970-46B4BAA9-3056-47A5-92AE-B5126E672FEB @default.
- Q66065970 P582 Q66065970-D324A908-9C06-4A21-B883-DAA088CDF05F @default.
- Q66065970 P6099 Q66065970-478DF69E-E075-4586-A36A-CCD314182BDA @default.
- Q66065970 P6153 Q66065970-78806CE7-3313-4FFF-A05B-6FC68EF10F09 @default.
- Q66065970 P6153 Q66065970-CD11CE87-C5D9-429D-BF01-DD1E5D158ECD @default.
- Q66065970 P8363 Q66065970-B8843E21-7185-43CC-A8C0-77676BC44F65 @default.
- Q66065970 P859 Q66065970-9156B37D-7EE7-4D9E-8F93-BAE360E93B0A @default.
- Q66065970 P1050 Q180614 @default.
- Q66065970 P1132 "+260" @default.
- Q66065970 P1476 "A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination With Ipilimumab or Ipilimumab Alone in Participants With Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 Therapy" @default.
- Q66065970 P17 Q30 @default.
- Q66065970 P2899 "+18" @default.
- Q66065970 P3098 "NCT03978611" @default.
- Q66065970 P31 Q30612 @default.
- Q66065970 P580 "2019-06-11T00:00:00Z" @default.
- Q66065970 P582 "2024-05-31T00:00:00Z" @default.
- Q66065970 P6099 Q5452194 @default.
- Q66065970 P6153 Q54559592 @default.
- Q66065970 P6153 Q5874290 @default.
- Q66065970 P8363 Q78089383 @default.
- Q66065970 P859 Q266423 @default.